HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

NEW YORK and VIENNA, Austria, Nov. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. HOOK ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in two upcoming virtual investor conferences:

• The SVB Leerink Oncology 1x1 Day, November 19, 2020
• The Piper Sandler 32^nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020

HOOKIPA will participate in virtual one-on-one meetings during these events.

About HOOKIPA
HOOKIPA Pharma Inc. HOOK is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, non-replicating (VaxWave^®) and replicating (TheraT^®), induce robust antigen-specific CD8⁺ T cells and pathogen-neutralizing antibodies. HOOKIPA's viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8⁺ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA's non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact: